2018
Inflammatory cues induce expression of immune checkpoint molecule CD137 in breast cancer cells
FRIEDLOVÁ, Nela; Monika DÚCKA; Petr BENEŠ a Lucia KNOPFOVÁZákladní údaje
Originální název
Inflammatory cues induce expression of immune checkpoint molecule CD137 in breast cancer cells
Autoři
FRIEDLOVÁ, Nela; Monika DÚCKA; Petr BENEŠ a Lucia KNOPFOVÁ
Vydání
Molecular Patholology Days, 14.-15. 6. 2018, Olomouc. 2018
Další údaje
Typ výsledku
Konferenční abstrakt
Utajení
není předmětem státního či obchodního tajemství
Označené pro přenos do RIV
Ne
ISBN
978-80-7471-234-0
Změněno: 21. 1. 2019 21:01, Mgr. Nela Friedlová, Ph.D.
Anotace
V originále
CD137 (Tumor Necrosis Factor Receptor Superfamily, Member 9) was originally described as a T cell co-stimulatory molecule. In context of cancer it is a valuable target for immunotherapy, as the agonist CD137 antibodies induce potent T cell-mediated anti-tumor immunity. However, tumor cells utilize CD137-based strategies, such as expression of its soluble variant, in order to prevent co-stimulation of T lymphocytes. Besides, immune checkpoint molecules have been shown to promote the epithelial-mesenchymal transition, the acquisition of tumor-initiating potential and resistance to apoptosis and antitumor drugs, as well as the propensity to disseminate and metastasize. Autocrine and paracrine effects of CD137 receptor/ligand bidirectional signaling in breast cancer are still only marginally understood. We have recently described that CD137 expression is downregulated by metastasis suppressor c-Myb in mammary cancer cells. On contrary, its expression is induced by inflammatory stimuli, such as TNF. We explore how tumor-derived CD137 affects breast cancer biology and interactions with immune/stromal cells.
Návaznosti
| GJ17-08985Y, projekt VaV |
| ||
| MUNI/C/1433/2017, interní kód MU |
|